EDITAS MEDICINE, INC. Marketable Securities (Current)
EDITAS MEDICINE, INC. (EDIT) had Marketable Securities (Current) of $29.83 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-05
- 2026-06-30: Marketable Securities, Current $29.83M.
- 2025-12-31: Marketable Securities, Current $0.00.
- 2025-09-30: Marketable Securities, Current $0.00.
- 2025-06-30: Marketable Securities, Current $39.96M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $29.83M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $39.96M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $82.27M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $138.37M 10-K · filed 2026-03-09 |
| 2024-09-30 | $169.26M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $214.67M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $226.94M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $199.46M 10-K · filed 2025-03-05 |
| 2023-09-30 | $267.08M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $211.15M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $189.42M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $202.75M 10-K · filed 2024-02-28 |
| 2022-09-30 | $208.91M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $283.16M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $277.48M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $296.33M 10-K · filed 2023-02-22 |
| 2021-09-30 | $297.96M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $272.72M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $270.42M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $262.43M 10-K · filed 2022-02-24 |
| 2020-09-30 | $215.73M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $112.90M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $182.14M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $218.96M 10-K · filed 2021-02-26 |
| 2019-09-30 | $227.84M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $107.33M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $184.13M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $234.18M 10-K · filed 2020-02-26 |
| 2018-09-30 | $225.79M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $212.16M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $141.15M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $182.51M 10-K · filed 2019-03-01 |
| 2017-09-30 | $209.15M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $180.70M 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |